Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.60 |
| ▸ | DRD4 | P21917 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11738164 | 0.83 | OPRM1 (0.77) | OPRM1DRD4KCNH2SLC22A1SLC6A4 | |
| Hydrochloric Acid SCHEMBL11747049 | 0.81 | OPRM1 (0.74) | OPRM1DRD4KCNH2SLC22A1SLC6A4 | |
| SCHEMBL2773343 | 0.80 | OPRM1 (0.47) | OPRM1DRD4KCNH2SLC6A4 | |
| SCHEMBL57461 | 0.79 | PNMT (0.54) | — | |
| SCHEMBL16418421 | 0.79 | OPRM1 (0.73) | OPRM1DRD4KCNH2GRIN2DGRIN3B | |
| SCHEMBL6888869 | 0.79 | OPRM1 (0.53) | OPRM1DRD4OPRD1OPRK1 | |
| SCHEMBL3028217 | 0.77 | DRD4 (0.58) | OPRM1DRD4 | |
| SCHEMBL13234639 | 0.77 | DRD4 (0.58) | OPRM1DRD4 | |
| Hydrochloric Acid SCHEMBL665781 | 0.77 | PNMT (0.52) | — | |
| SCHEMBL684582 | 0.77 | OPRD1 (0.62) | OPRM1DRD4KCNH2SLC22A1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114213255-A | Synthetic method of six-membered ring benzylamine compound | 上海泰坦科技股份有限公司 | 2022-03-22 | — | — | CN | disclosed |
| WO-2019115008-A1 | DIALKYLAMINOARYLPIPERIDINYL-O-PHENOXY AND O-BENZYLOXYPROPYLAMINO DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-06-20 | — | — | WO | disclosed |
| US-9458160-B2 | Peripherally restricted diphenyl purine derivatives | RESEARCH TRIANGLE INSTITUTE (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160046630-A1 | PERIPHERALLY RESTRICTED DIPHENYL PURINE DERIVATIVES | RES TRIANGLE INST (US) | 2016-02-18 | — | — | US | disclosed |
| US-9187480-B2 | Peripherally restricted diphenyl purine derivatives | RESEARCH TRIANGLE INSTITUTE (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150031689-A1 | PERIPHERALLY RESTRICTED DIPHENYL PURINE DERIVATIVES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-01-29 | — | — | US | disclosed |
| WO-2013024895-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-02-21 | — | — | WO | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-2420491-A1 | 3 , 5-substitued piperidine compounds as renin inhibitors | Novartis AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| EP-2420491-A1 | 3 , 5-substitued piperidine compounds as renin inhibitors | Novartis AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-7704996-B2 | Compounds and compositions useful as cathepsin S inhibitors | NOVARTIS AG (CH) | 2010-04-27 | — | — | US | disclosed |
| US-7704996-B2 | Compounds and compositions useful as cathepsin S inhibitors | NOVARTIS AG (CH) | 2010-04-27 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| WO-2009050248-A1 | SUBSTITUTED PIPERIDINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
| US-20090048230-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | NOVARTIS AG (CH) | 2009-02-19 | — | — | US | disclosed |
| US-20090048230-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | NOVARTIS AG (CH) | 2009-02-19 | — | — | US | disclosed |
| EP-1968940-A1 | 3 , 5-SUBSTITUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | Novartis AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007077005-A1 | 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2007-07-12 | — | — | WO | disclosed |
| WO-2006018284-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | NOVARTIS AG (CH) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | OPRM1 95/4885DRD4 268/4885KCNH2 415/4885 |
| US-20150031689-A1 | PERIPHERALLY RESTRICTED DIPHENYL PURINE DERIVATIVES | CNR1, CNR2, P2RY1 | OPRM1 33/4885DRD4 384/4885KCNH2 3811/4885 |
| US-20090048230-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | CTSS, CTSZ, CTSF | OPRM1 2515/4885DRD4 3894/4885KCNH2 3867/4885 |
| US-20160046630-A1 | PERIPHERALLY RESTRICTED DIPHENYL PURINE DERIVATIVES | CNR1, CNR2, P2RY1 | OPRM1 33/4885DRD4 384/4885KCNH2 3811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.